Cencora, Inc. is a pharmaceutical sourcing and distribution services company. It operates through the United States (U.S.) Healthcare Solutions and International Healthcare Solutions segments. The U.S. Healthcare Solutions segment focuses on the distribution of specialty, brand-name, and generic pharmaceuticals. The International Healthcare Solutions segment includes pharmaceutical wholesale, related operations, and global commercialization services. The company was founded by Emil P. Martini in 1947 and is headquartered in Conshohocken, PA.
相关临床试验
0
0 进行中
药物批准
53
批准总数
监管机构
1
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
- Cencora launched Cell and Gene Therapy Enablement through its Accelerate Pharmacy Solutions portfolio on September 2, 2026, to help health systems evaluate, build, and scale cell and gene therapy programs. - Only 4% of health system pharmacy leaders report being fully prepared to integrate cell and gene therapies, despite more than 35 FDA approvals and over 1,700 clinical trials underway globally. - The offering provides tailored support across three pillars: financial confidence, operational readiness, and scalable growth, spanning market assessment, governance design, and workflow planning. - Cencora executives emphasize that fulfilling the clinical promise of these therapies requires health systems to strategically expand capabilities and collaborate across industry silos.
- The median real-world vein-to-vein time for a leading CAR-T therapy is 27 days, and shorter intervals are associated with meaningfully better complete-response rates and survival. - Most cell and gene therapies require storage at −150°C or colder, far beyond conventional pharmaceutical cold chain capabilities, with fresh un-frozen cells degrading within 12–96 hours. - Hospital readiness remains the defining access barrier across APAC, with Tier-2 regional centres frequently unqualified to receive cryogenic therapies even when the cold chain reaches the airport. - Point-of-care manufacturing, exemplified by India's NexCAR19 priced near US$50,000, offers an alternative model with vein-to-vein times of 7–14 days and no intercontinental cold chain dependency.
- Cencora has entered an agreement with Kite, a Gilead company, to distribute the FDA-approved CAR T-cell therapies Yescarta and Tecartus across the United States. - The collaboration aims to support an expanding network of authorized treatment centers, including health systems and community oncology practices, bringing therapies closer to patients. - Cencora will leverage its cell and gene therapy services platform to manage logistics, order management, and site support, reducing administrative burdens for healthcare providers. - The agreement reflects a broader industry trend toward expanding access to complex cell and gene therapies beyond large academic hospitals into community-based care settings.
- Cencora has entered a major U.S. distribution partnership with Kite Pharma, a Gilead company, to support FDA-approved CAR T cell therapies across treatment centers. - The agreement focuses on market access and distribution support, aiming to ease logistical and administrative hurdles for healthcare providers using these personalized cancer treatments. - The collaboration highlights Cencora's growing role in complex therapy and specialized distribution, potentially influencing how investors view its position in next-generation treatment logistics. - Cencora's stock trades at $279.57, roughly 25% below the $350.58 analyst consensus target, with shares flagged as undervalued at 42.6% below estimated fair value.
- Cencora announced a $1.1 billion acquisition of EyeSouth Partners' retina business to strengthen its specialty medical services division. - The deal will integrate EyeSouth's retina-focused physicians into Cencora's existing eye-care arm, Retina Consultants of America. - This marks the third major retina-focused eye-care network acquisition by a distributor, following similar moves by competitors in the consolidating market. - The transaction is expected to be slightly accretive to adjusted earnings per share in the first twelve months after closing.
- Gallant announced a landmark partnership with MWI Animal Health to create the first-ever ultra-low temperature cold chain for veterinary medicine, supporting the anticipated first FDA-approved off-the-shelf stem cell therapy for pets. - The collaboration will enable delivery of sonruvetcel, a potential first-in-class uterine-derived mesenchymal stromal cell therapy for cats with refractory feline chronic gingivostomatitis, requiring storage at -80°C. - Survey data shows 95% of veterinary professionals believe stem cell therapy will become standard treatment within the next decade, with 93% more likely to offer regenerative therapies if they were off-the-shelf and delivered through simple IV protocols. - The partnership establishes infrastructure to support Gallant's broader pipeline of disease-modifying therapies targeting inflammatory and degenerative conditions in companion animals.
- Curant Rare and Cencora announced a strategic collaboration to provide pharmaceutical companies with integrated solutions for commercializing rare disease therapies. - The partnership combines Cencora's pharmaceutical logistics and commercialization solutions with Curant Rare's specialty pharmacy services to address unique challenges in rare disease therapy access. - The collaboration aims to streamline commercialization pathways, optimize patient journeys, and expedite speed-to-therapy for rare and orphan drug products. - Pharmaceutical companies will gain access to advanced tools including real-world evidence insights and patient-reported outcomes to improve patient experiences.
- Cencora announced a collaboration with Curant Health's Curant Rare division on January 22, 2026, combining commercialization capabilities with specialty pharmacy services for rare disease therapies. - The partnership aims to provide rare disease drug developers with integrated access to real-world evidence, patient-reported outcomes, and market access support to navigate regulatory hurdles. - This collaboration reinforces Cencora's strategic shift toward higher-value specialty services, following recent acquisitions including the $5 billion OneOncology deal and $4.6 billion Retina Consultants of America purchase. - The move aligns with Cencora's long-term growth strategy, as the company raised its adjusted operating income growth guidance to 7-10% and earnings per share growth to 10-14%.
- McKesson Corporation has secured distribution agreements for two novel oncology therapies, LYMPHIR and PHYRAGO, reinforcing its position in the specialty pharmaceutical market. - LYMPHIR, an FDA-approved immunotherapy for cutaneous T-cell lymphoma developed by Citius Oncology, will be distributed nationwide through McKesson's network. - PHYRAGO, Cycle Pharmaceuticals' first oncology product launched in partnership with Handa Therapeutics, is exclusively available through Onco360 with McKesson providing distribution support. - These partnerships demonstrate McKesson's strategic focus on high-growth therapeutic areas and its role in making complex cancer treatments broadly accessible to patients across the United States.
- Outlook Therapeutics awaits FDA decision by August 27, 2025, for LYTENAVA (bevacizumab-vikg), which would be the first FDA-approved ophthalmic formulation of bevacizumab in the U.S. with 12 years of regulatory exclusivity. - The company has already secured regulatory approval in the European Union and UK, with successful commercial launches in Germany and UK, including endorsements from NICE and Scottish Medicines Consortium. - LYTENAVA targets the $4 billion+ anti-VEGF market for wet AMD, potentially capturing 20-30% market share by replacing 2.7 million annual off-label bevacizumab injections in the U.S. - New CEO Bob Jahr brings 20 years of commercial expertise to navigate the critical commercialization phase, though the company faces financial challenges with $8.9 million in cash reserves as of June 2025.
